Department of Health Services, 650 Charles E, Young Drive S, 61-253 CHS, Los Angeles, CA 90095, USA.
BMC Cancer. 2011 Mar 7;11:92. doi: 10.1186/1471-2407-11-92.
The Mayo Lung Project (MLP), a randomized controlled clinical trial of lung cancer screening conducted between 1971 and 1986 among male smokers aged 45 or above, demonstrated an increase in lung cancer survival since the time of diagnosis, but no reduction in lung cancer mortality. Whether this result necessarily indicates a lack of mortality benefit for screening remains controversial. A number of hypotheses have been proposed to explain the observed outcome, including over-diagnosis, screening sensitivity, and population heterogeneity (initial difference in lung cancer risks between the two trial arms). This study is intended to provide model-based testing for some of these important arguments.
Using a micro-simulation model, the MISCAN-lung model, we explore the possible influence of screening sensitivity, systematic error, over-diagnosis and population heterogeneity.
Calibrating screening sensitivity, systematic error, or over-diagnosis does not noticeably improve the fit of the model, whereas calibrating population heterogeneity helps the model predict lung cancer incidence better.
Our conclusion is that the hypothesized imperfection in screening sensitivity, systematic error, and over-diagnosis do not in themselves explain the observed trial results. Model fit improvement achieved by accounting for population heterogeneity suggests a higher risk of cancer incidence in the intervention group as compared with the control group.
梅奥肺计划(MLP)是一项在 1971 年至 1986 年间针对年龄在 45 岁或以上的男性吸烟者进行的肺癌筛查的随机对照临床试验,该试验表明自诊断以来肺癌的存活率有所提高,但肺癌死亡率并未降低。这一结果是否必然表明筛查没有带来生存获益仍存在争议。提出了许多假说以解释观察到的结果,包括过度诊断、筛查敏感性和人群异质性(试验组之间肺癌风险的初始差异)。本研究旨在为其中一些重要论点提供基于模型的检验。
我们使用微模拟模型 MISCAN-lung 模型,探讨了筛查敏感性、系统误差、过度诊断和人群异质性的可能影响。
调整筛查敏感性、系统误差或过度诊断并不会明显改善模型的拟合度,而调整人群异质性有助于模型更好地预测肺癌发病率。
我们的结论是,假设的筛查敏感性、系统误差和过度诊断不完美本身并不能解释观察到的试验结果。通过考虑人群异质性来提高模型拟合度表明,与对照组相比,干预组的癌症发病率更高。